{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:57:24Z","timestamp":1788983844630,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT21LK11"],"award-info":[{"award-number":["DUT21LK11"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274006"],"award-info":[{"award-number":["82274006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.critrevonc.2024.104298","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:13:20Z","timestamp":1707999200000},"page":"104298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Higher risk of hepatotoxicity associated with cabozantinib in cancer patients"],"prefix":"10.1016","volume":"196","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-8186","authenticated-orcid":false,"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2024.104298_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104298_bib2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem. Res Toxicol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104298_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.eururo.2018.11.033","article-title":"Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint","volume":"75","author":"Basch","year":"2019","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104298_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2020.12.005","article-title":"Updated European Association of Urology Guidelines on Renal Cell Carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-na\u00efve metastatic clear-cell renal cell carcinoma","volume":"79","author":"Bedke","year":"2021","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104298_bib5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104298_bib6","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104298_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104298_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104298_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104298_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104298_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.critrevonc.2024.104298_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102221","article-title":"Cabozantinib: An evolving therapy for hepatocellular carcinoma","volume":"98","author":"El-Khoueiry","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2024.104298_bib13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. \u3008https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5\u00d711.pdf\u3009. (Accessed 14 March 2023)."},{"key":"10.1016\/j.critrevonc.2024.104298_bib14","unstructured":"Exelixis Inc. 2012. CABOMETYX (cabozantinib) tablets, for oral use: US prescribing information. \u3008http:\/\/www.accessdata.fda.gov\/\u3009. (Accessed 20 March 2023)."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104298_bib15","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104298_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/TP.0b013e3181daac69","article-title":"Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient","volume":"90","author":"Herden","year":"2010","journal-title":"Transplantation"},{"issue":"7414","key":"10.1016\/j.critrevonc.2024.104298_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"5s","key":"10.1016\/j.critrevonc.2024.104298_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.6004\/jnccn.2018.0039","article-title":"Updates to the Management of Kidney Cancer","volume":"16","author":"Jonasch","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104298_bib19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104298_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1186\/s12885-018-4891-7","article-title":"Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104298_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104298_bib22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104298_bib23","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104298_bib24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/tx900256y","article-title":"Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities","volume":"22","author":"Li","year":"2009","journal-title":"Chem. Res Toxicol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104298_bib25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.109.030361","article-title":"Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104298_bib26","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104298_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib","volume":"104","author":"Llanos","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104298_bib28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"152","author":"Matulonis","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104298_bib29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1592\/phco.28.8.1066","article-title":"Sunitinib-related fulminant hepatic failure: case report and review of the literature","volume":"28","author":"Mueller","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104298_bib30","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104298_bib31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jcph.510","article-title":"Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK","volume":"55","author":"Nguyen","year":"2015","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104298_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","article-title":"Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells","volume":"395","author":"Paech","year":"2018","journal-title":"Toxicology"},{"issue":"10275","key":"10.1016\/j.critrevonc.2024.104298_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104298_bib34","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/med.21577","article-title":"Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: implications for drug-drug interactions and hepatotoxicity","volume":"39","author":"Paludetto","year":"2019","journal-title":"Med Res. Rev."},{"issue":"25","key":"10.1016\/j.critrevonc.2024.104298_bib35","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104298_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104298_bib37","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2024.104298_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/03602532.2022.2149775","article-title":"Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice","volume":"55","author":"Yan","year":"2023","journal-title":"Drug Metab. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104298_bib39","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00204-016-1918-1","article-title":"Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria","volume":"91","author":"Zhang","year":"2017","journal-title":"Arch. Toxicol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T17:40:04Z","timestamp":1715449204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"alternative-id":["S1040842824000416"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104298","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher risk of hepatotoxicity associated with cabozantinib in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104298"}}